Emcure Pharmaceuticals Share Price
Start SIP in Emcure Pharmaceuticals
Start SIPEmcure Pharmaceuticals Performance
Day Range
- Low 1,385
- High 1,416
52 Week Range
- Low 1,225
- High 1,455
- Open Price1,415
- Previous Close1,405
- Volume84378
Emcure Pharmaceuticals Investment Rating
-
Master Rating:
-
Emcure Pharmaceuticals Ltd has an operating revenue of Rs. 11,128.47 Cr. on a trailing 12-month basis. An annual revenue growth of 2% is not great, Pre-tax margin of 12% is healthy, ROE of 21% is exceptional. The company has a reasonable debt to equity of 30%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 5% and 5% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around -0% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 27 which is a POOR score indicating inconsistency in earnings, a RS Rating of 25 which is POOR indicating the underperformance as compared to other stocks, Group Rank of 101 indicates it belongs to a poor industry group of Medical-Supplies and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Jun 2024 | Mar 2024 | Jun 2023 |
|---|---|---|---|
| Oper Rev Qtr Cr | 970 | 903 | 837 |
| Operating Expenses Qtr Cr | 855 | 796 | 725 |
| Operating Profit Qtr Cr | 115 | 106 | 111 |
| Depreciation Qtr Cr | 55 | 39 | 39 |
| Interest Qtr Cr | 38 | 56 | 46 |
| Tax Qtr Cr | 15 | 6 | 12 |
| Net Profit Qtr Cr | 40 | 29 | 36 |
Emcure Pharmaceuticals Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 6
- Bearish Moving Average
- ___
- 3
- 20 Day
- ₹1,368.86
- 50 Day
- ₹
- 100 Day
- ₹
- 200 Day
- ₹
- 20 Day
- ₹1,351.90
- 50 Day
- ₹
- 100 Day
- ₹
- 200 Day
- ₹
Emcure Pharmaceuticals Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 1,411.87 |
| Second Resistance | 1,429.43 |
| Third Resistance | 1,442.87 |
| RSI | 57.09 |
| MFI | 77.30 |
| MACD Single Line | 14.71 |
| MACD | 21.08 |
| Support | |
|---|---|
| First Support | 1,380.87 |
| Second Support | 1,367.43 |
| Third Supoort | 1,349.87 |
Emcure Pharmaceuticals Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 89,012 | 5,105,728 | 57.36 |
| Week | 150,868 | 8,688,511 | 57.59 |
| 1 Month | 233,832 | 12,070,420 | 51.62 |
| 6 Month | 219,611 | 13,139,333 | 59.83 |
Emcure Pharmaceuticals Result Highlights
Emcure Pharmaceuticals Synopsis
NSE-Medical-Supplies
Emcure Pharmaceutica is involved in the business activities of Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 3107.09 Cr. and Equity Capital is Rs. 180.85 Cr. for the Year ended 31/03/2023. Emcure Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 16/04/1981 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is U24231PN1981PLC024251 and registration number is 024251.| Market Cap | 26,366 |
| Sales | 1,873 |
| Shares in Float | 4.16 |
| No of funds | |
| Yield |
| Book Value | 13.69 |
| U/D Vol ratio | 0.3 |
| LTDebt / Equity | 33 |
| Alpha | 0.02 |
| Beta | 0.91 |
Emcure Pharmaceuticals Shareholding Pattern
| Owner Name |
|---|
Emcure Pharmaceuticals Management
| Name | Designation |
|---|---|
| Mr. Berjis Minoo Desai | Chairman & Non-Exe.Director |
| Mr. Satish Ramanlal Mehta | Managing Director & CEO |
| Mr. Sunil Rajanikant Mehta | Whole Time Director |
| Ms. Namita Vikas Thapar | Whole Time Director |
| Mr. Samit Satish Mehta | Whole Time Director |
| Mr. Mukund Keshao Gurjar | Whole Time Director |
| Mr. Samonnoi Sajani Banerjee | Director |
| Mr. Palamadai Sundararajan Jayakumar | Director |
| Mr. Vijay Keshav Gokhale | Director |
| Ms. Vidya Rajiv Yeravdekar | Director |
| Mr. Shailesh Kripalu Ayyangar | Director |
Emcure Pharmaceuticals Forecast
Price Estimates
Emcure Pharmaceuticals Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2024-08-13 | Quarterly Results |
Emcure Pharmaceuticals FAQs
What is Share Price of Emcure Pharmaceuticals ?
Emcure Pharmaceuticals share price is ₹1,394 As on 08 September, 2024 | 05:27
What is the Market Cap of Emcure Pharmaceuticals ?
The Market Cap of Emcure Pharmaceuticals is ₹26366 Cr As on 08 September, 2024 | 05:27
What is the P/E ratio of Emcure Pharmaceuticals ?
The P/E ratio of Emcure Pharmaceuticals is As on 08 September, 2024 | 05:27
What is the PB ratio of Emcure Pharmaceuticals ?
The PB ratio of Emcure Pharmaceuticals is 8.4 As on 08 September, 2024 | 05:27